Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro
Latest Information Update: 08 May 2024
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms GAZAI
- 08 May 2024 Status changed from active, no longer recruiting to completed.
- 10 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 25 Aug 2021 Planned End Date changed from 1 Sep 2023 to 1 May 2024.